Immunovant’s investigational drug, batoclimab, demonstrated strong efficacy in a mid-stage study for Graves’ disease, leading to a significant rise in IMVT stock. The drug showed a remarkable reduction in Immunoglobin G levels and a high response rate in patients, highlighting a potential treatment option for this often-uncontrolled condition.
Immunovant, Inc. (IMVT) reported positive results from its Phase 2a trial of batoclimab in Graves’ Disease, a condition affecting the thyroid gland. The drug showed significant IgG reduction and a high response rate in patients, leading to a potential first-in-class treatment. Immunovant has aligned with the FDA and plans to initiate a pivotal trial by the end of 2024.
